Publications
Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast cancer research and treatment. 2017. PMID: 28324268
Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. Journal for immunotherapy of cancer. 2017. PMID: 28344808
West ES, Shinkai K, Ai WZ, Pincus LB. Remission of subcutaneous panniculitis-like T-cell lymphoma in a pregnant woman after treatment with oral corticosteroids as monotherapy. JAAD case reports. 2017. PMID: 28361107
Neel DS, Bivona TG. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. NPJ precision oncology. 2017. PMID: 29152593
Le TX, Wolf JL, Peralta CA, Webber AB. Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017. PMID: 28320553
Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. The oncologist. 2017. PMID: 28314838
Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science (New York, N.Y.). 2017. PMID: 28302823
Oh DY,* Cham J,* Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. *co-first author.. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire Cancer Res.. 2017. PMID:
Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European urology. 2017. PMID: 28314611
Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. The Lancet. Oncology. 2017. PMID: 28314691
Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017. PMID: 28298546
Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians. 2017. PMID: 28294295
Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget. 2017. PMID: 29069718
Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Scientific Reports. 2017. PMID: 28287179
Melisa L. Wong, Hala Borno, Reena Mahajan, Kara E. Bischoff, Brook Calton, Emily K. Bergsland, Won Kim, Rahul Raj Aggarwal, Katy K. Tsai, Pelin Cinar. Improving documentation of surrogate decision makers in medical oncology clinic. Journal of Clinical Oncology. 2017. PMID:
Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nature reviews. Drug discovery. 2017. PMID: 28280262
Rugo HS, Rossi G, Rizzi G, Aapro M. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. Breast (Edinburgh, Scotland). 2017. PMID: 28285236
Mark S, Cataldo J, Dhruva A, Paul SM, Chen LM, Hammer MJ, Levine JD, Wright F, Melisko M, Lee K, Conley YP, Miaskowski C. Modifiable and non-modifiable characteristics associated with sleep disturbance in oncology outpatients during chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017. PMID: 28281049
Rugo HS, Melin SA, Voigt J. Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast cancer research and treatment. 2017. PMID: 28275922
Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A. Treating Multiple Myeloma Patients With Oral Therapies. Clinical lymphoma, myeloma & leukemia. 2017. PMID: 28347676